Uric acid and uric acid/creatinine ratio and their correlations with the hemorheological determinants in subjects with subclinical carotid atherosclerosis
Restricted accessResearch articleFirst published online April 23, 2022
Uric acid and uric acid/creatinine ratio and their correlations with the hemorheological determinants in subjects with subclinical carotid atherosclerosis
we have examined the concentration of serum uric acid and the serum uric acid/creatinine ratio as well as their correlations with the main determinants of the hemorheological profile in a group of subjects with subclinical carotid atherosclerosis.
METHODS:
we evaluated the concentration of serum uric acid and the serum uric acid/creatine ratio in 43 men and 57 women [median age 66.00 (25)] with subclinical carotid atherosclerosis, subsequently divided according to the number of traditional cardiovascular risk factors and to the insulin resistance degree.
RESULTS:
serum uric acid, but not the serum uric acid/creatinine ratio, results strongly influenced by the number of cardiovascular risk factors and by the insulin resistance degree. In the whole group and in the subgroups of subclinical carotid atherosclerosis subjects, serum uric acid and serum uric acid/creatinine ratio show significant correlation, besides with whole blood viscosity, with plasma viscosity and erythrocyte aggregation. The influence of the serum uric acid on the erythrocyte aggregability that is a part of the erythrocyte aggregation is to ascribe to the action carried out by serum uric acid on the erythrocyte zeta potential.
CONCLUSIONS:
it is reasonable to think that the treatment of the asymptomatic or symptomatic hyperuricemia with the urate-lowering therapy that reduces the serum uric acid concentration may reflect on the hemorheological profile which role on the atherosclerotic cardiovascular disease is well known.
CaimiG, UrsoC, BrucculeriS, AmatoC, CarlisiM, Lo PrestiR. An assessment of the hemorheological profile in patients with subclinical carotid atherosclerosis divided in relation to the number of cardiovascular risk factors and different degrees of insulin resistance. Clin Hemorheol Microcirc. 2021;78:417–28.
2.
Salazar-LugoR, BarahonaA, TarupiY, VictoriaC, SantamariaM, OleasM. Biochemical and nutritional factors associated with blood viscosity in adults living in a mountain chain, (Imbubara),Ecuador. Invest Clin. 2016;57:293–304.
3.
HerranzB, AlvarezMD, Perez-JemenezJ. Association of plasma and urine viscosity with cardiometabolic risk factors and oxidative status. A pilot study in subjects with abdominal obesity. PloS One. 2018;13:e0204075.
4.
HoieggenA, FossumE, ReimesH, KjeldsenE. Serum uric acid and hemorheology in borderline hypertensives and in subjects with established hypertension and left ventricular hypertrophy. Blood Press. 2003;12:104–10.
5.
StelmachMJ, SzczerbinskiL, WasilewskaN, ProtasP, WasilewskaA. Hematological parameters in adolescents with hyperuricemia. Indian Pediatr. 2014;51:1003–5.
6.
CabelM, MeiselmanHJ, PopelAS, JohnsonPC. Contribution of red blood cell aggregation to venous vascular resistance in skeletal muscle. Am J Physiol. 1997;272(2 Pt 2):H1020–32.
7.
RamplingMW, MeiselmanHJ, NeuB, BaskurtOK. Influence of cell-specific factors on red blood cell aggregation. Biorheology. 2004;41(2):91–112.
8.
NeuB, MeiselmanHJ. Red blood cell aggregation. In: Handbook of hemorheology and hemodynamics. Ed Baskurt OK, Hardeman MR, Rampling MW, Meiselman HJ. IOS Press2007, pp. 114–136.
9.
FernandesHP, CesarCL, Barjas-CastroML. Electrical properties of the red blood cell membrane and immunohematological investigation. Rev Bras Hematol Hemoter. 2011;33:297–301.
10.
PollackW, ReckelRP. A reppraisal of the forces involved in hemagglutination. Int Archs Allergy Appl Immun. 1977;54:29–42.
11.
TokumasuF, OsteraGR, AmaratungC, FairhurstRM. Modification in erythrocyte membrane zeta potential by plasmodium falciparum infection. Exp Parasitol. 2012;131:245–51.
12.
AdakS, ChowdhuryS, BhattacharyyaM. Dynamic and electrokinetic behaviour of erythrocyte membrane in diabetes mellitus and diabetic cardiovascular disease. Biochim Biophys Acta. 2008;1780:108–15.
ElblbesyM, MoustafaME. The impact of biophysical properties of erythrocytes on their aggregation. Int J of Biomed Sci. 2017;13:113–8.
15.
HuangY-X, WuZ-J, MehrishiJ, HuangB-T, ChenX-Y, ZhengX-j, LiuW-J, LuoM. Human red blood cell aging: correlative changes in surface charge and cell properties. J Cell Mol Med. 2011;15:2634–42.
16.
SilvaDCN, JovinoCN, SilvaCAL, FernandesHP, FilhoMM, LucenaSC, CostaAMDN, CesarCL, Barjas-CastroML, SantosBS. Optical tweezers as a new biomedical tool to measure zeta potential of stored red blood cells. PLoS ONE. 2012;7:e31778.
17.
GaikwadSS, AvariJG. Effect on morphology,osmotic fragility and electro kinetic potential of erythrocytes in hypertension. Curr Hypertens Rev. 2017;13:132–7.
18.
SloopGD, BialczakJK, WeidmanJJ, St CyrJA. Uric acid increases erythrocyte aggregation: implication for cardiovascular disease. Clin Hemorheol Microcirc. 2016;63:349–59.
19.
SloopGD. The role of blood viscosity and hemodynamics in atherothrombosis. In: Blood Viscosity. Its role in cardiovascular pathophysiology and hematology. Sloop G.D. Editor- Nova Science Publishers, Inc. New York2017, pp. 35–53.
20.
BurtHM, EvansE, LamEW, GehrsPF, HerringFG. Membranolytic effects of crystalline monosodium urate monohydrate: influence of grinding. J Rheumatol. 1986;13:778–83.
21.
BurtHM, JacksonJK, KimKJ. Role of membrane proteins in monosodium urate crystal-membrane interactions. I. Effect of pretreatment of erythrocyte membranes with glutaraldehyde and neuraminidase. J Rheumatol. 1990;17:1353–8.
22.
BurtHM, JacksonJK. Role of membrane proteins in monosodium urate crystal-membrane interactions. II. Effect of pretreatments of erythrocyte membranes with membrane permeable and impermeable protein crosslinking agents. J Rheumatol. 1990;17:1359–63.
23.
JinYL, ZhuT, XuL, ZhangWS, LiuB, JiangCQ, YuH, HuangLM, ChengKK, ThomasCN, LamTH. Uric acid levels, even in the normal range, are associated with increased cardiovascular risk: The Guangzhou Biobank Cohort Study. Int J of Cardiol. 2013;168:2238–41.
24.
BromboG, BonettiF, VolpatoS, MorieriML, NapoliE, BandinelliS, CherubiniA, MaggioM, GuralnikJ, FerrucciL, ZulianiG. Uric acid within the “normal” range predict 9-year cardiovascular mortality in older individuals. The InCHIANTI study. Nutr Metab Cardiovascular Dis. 2019;29:1061–7.
25.
YouH, ChenK, HanP, YueC, ZhaoX. U-shaped relationship between cardiovascular mortality and serum uric acid may be attributed to stroke-and heart- specific mortality, respectively, among hypertensive patients: a national representative cohort study. Med Sci Monit. 2021;27:e928937.
26.
DrivelegkaP, Forsblad-d’EliaH, AngeråsO, BergströmG, SchmidtC, JacobssonLTH, DehlinM. Association between serum level of urate and subclinical atherosclerosis: results from the SCAPIS Pilot. Arthritis Res Ther. 2020;22:37.
27.
WuJ, QiuL, ChengXQ, XuT, WuW, ZengXJ, YeYC, GuoXZ, ChengQ, LiuQ, LiuL, XuCL, ZhuGJ. Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population. Sci Rep. 2017;7:5456.
28.
DobrzyńskaM, PrzysławskiJ. The relationship between serum uric acid concentration and cardiovascular risk factors in normotensive postmenopausal women with dyslipidemia. Acta Sci Pol Technol Aliment. 2020;19:123–13.
29.
LiY, TianL, ZhengH, JiaC. Serum uric acid and risk of incident hypercholesterolaemia and hypertriglyceridaemia in middle-aged and older Chinese: a 4-year prospective cohort study. Ann Med. 2020;52:479–48.
30.
Sanchez-LozadaLG, Rodriguez-IturbeB, KelleyE, NakagawaT M, FeigDI, BorghiC, PianiF, Cara-FuentesG, BjornstadP, LanaspaMA, JohnsonRJ. Uric Acid and Hypertension: An Update With Recommendations. Am J Hypertens. 2020;33:583–94.
31.
PianiF, CiceroAFG, BorghiC. Uric Acid and Hypertension: Prognostic Role and Guide for Treatment. J Clin Med. 2021;10:448.
32.
van der SandeMA, WalravenGE, MilliganPJ, BanyaWA, CeesaySM, NyanOA, McAdamKP. Family history: an opportunity for early interventions and improved control of hypertension, obesity and diabetes. Bull World Health Organ. 2001;79:321–8.
33.
Torbus-LisieckaB, BukowskaH, JastrzebskaM, ChelstowskiK, HonczarenkoK, NaruszewiczM. Lp(a), homocysteine and a family history of early ischemic cerebral stroke. Nutr Metab Cardiovasc Dis. 2001;11(Suppl 5):52–9.
34.
KanbayM, JensenT, SolakY, LeM, Roncal-JimenezC, RivardC, LanaspaMA, NakagawaT, JohnsonRJ. Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med. 2016;29:3–8.
35.
AvulaNR, ShenoyD. Evaluation of Association of Hyperuricaemia with Metabolic Syndrome and Insulin Resistance. J Clin Diagn Res. 2016;10:OC32–OC34.
36.
KrishnanE, PandyaBJ, ChungL, HaririA, DabbousO. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol. 2012;176:108–16.
37.
GaitaL, TimarR, LupascuN, RomanD, AlbaiA, PotreO, TimarB. The Impact Of Hyperuricemia On Cardiometabolic Risk Factors In Patients With Diabetes Mellitus: A Cross-Sectional Study. Diabetes Metab Syndr Obes. 2019;12:2003–10.
38.
Haj MouhamedD, EzzaherA, NeffatiF, DoukiW, GahaL, NajjarMF. Effect of cigarette smoking on plasma uric acid concentrations. Environ Health Prev Med. 2011;16:307–12.
39.
TomitaM, MizunoS, YokotaK. Increased levels of serum uric acid among ex-smokers. J Epidemiol. 2008;18:132–4.
40.
KawamotoR, NinomiyaD, AkaseT, KikuchiA, KasaiY, KusunokiT, OhtsukaN, KumagiT. Serum uric acid to creatinine ratio independently predicts incident metabolic syndrome among community-dwelling persons. Metab Syndr and Relat Disord. 2019;20:1–9.
41.
TaoJ, ShenX, LiJ, ChaE, GuP-P, LiuJ, ZhuW, HeL-L, LiG-Q, WangZ. Serum uric acid to creatinine ratio and metabolic syndrome in postmenopausal Chinese women. Medicine. 2020;99:17(e19959).
42.
MinatoS, TakenouchiA, UchidaJ, TsuboiA, KurataM, FukuoK, KazumiT. Association of whole blood viscosity with matabolic syndrome in type 2 diabetic patents: independent association with post-breakfast triglyceridemia. J Clin Med Res. 2017;9:332–8.
43.
Taco-VasquezED, BarreraF, Serrano-DuenasM, JimenezE, RocutsA, PerezER. Association between blood viscosity and cardiovascular risk factors in patients with arterial hypertension in a high altitude setting. Cureus. 2019;11:e3925.
44.
YenF-S, HsuC-C, LiH-L, WeiJC-C, HwuC-M. Urate-lowering therapy may prevent the development of coronary artery disease in patients with gout. Front in Med. 2020;7:63.
45.
SaitoH, TanakaK, IwasakiT, OdaA, WatanabeS, KannoM, KimuraH, ShimabukuroM, AsahiK, WatanabeT, KazamaJJ. Xantine oxidase inhibitors are associated with reduced risk of cardiovascular disease. Sci Rep. 2021;11:1380.
